EASL Congress 2026 - Oral Presentation
May 28, 2026 at 5:00 PM CEST
Session: MASLD: Clinical and Therapeutic Aspects I (OS-016)
Title: Week 48 Top-Line Results from the Phase 2b, Multicenter, Randomized, Placebo-Controlled IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
Speaker: Dr. Mazen Noureddin, Professor of Medicine, Houston Methodist Hospital; Chief Scientific Officer and Co-Chairman, Summit Clinical Research
